Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PI3K-Inhibitor Registry Study: Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma

Next Previous
Trial Profile

PI3K-Inhibitor Registry Study: Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 18 Mar 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Duvelisib (Primary) ; 1 Phosphatidylinositol 3 kinase inhibitors
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms REAL
  • Sponsors Secura Bio

Most Recent Events

  • 15 Mar 2021 Planned End Date changed from 1 Apr 2023 to 31 Dec 2020.
  • 15 Mar 2021 Planned primary completion date changed from 1 Apr 2023 to 31 Dec 2020.
  • 15 Mar 2021 Status changed from recruiting to discontinued.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top